digital therapeutics Archives - Medical Design Sourcing

Decoding Bayer’s digital health leap and its implications on drug discovery and personalized medicine

The German multinational pharma and biotech colossus Bayer is taking further steps to ramp up its focus on digital health by launching a new business unit. In 2022, Bayer invested $9.5 million in Woebot Health, an AI-powered behavioral health platform company. In 2020, it launched a venture known as G4A Digital Health Partnership Program to drive digital collaboration in cardiometabolic and renal disease, oncology and women’s health.

This new unit, the Bayer Precision Health group, plans to focus on identifying digital and digital-supported consumer healthcare opportunities. The group seeks to create new precision health products based on real-world evidence and digital technologies.

Bayer’s new digital health unit has a priority mission. It seeks to cultivate pioneering digital technologies. The goal? Empower individuals to make more informed health choices. It aims to accomplish that objective by uncovering novel delivery mechanisms, as our sister…

Digital therapeutics open up new opportunities in medicine

Pear Therapeutics designed the reSET prescription digital therapeutic for the treatment of substance abuse disorder. [Image courtesy of Pear Therapeutics]A wide range of companies are aiming to make waves through digital therapeutic offerings, and each is doing things differently.

“We are seeing tremendous momentum for the DTx industry, with more and more products coming to market and gaining commercial coverage and recent signals from the White House and Congress demonstrating their interest and recognition of DTx products as an important way to expand access to quality treatments for populations with public coverage, especially underserved communities,” Digital Therapeutics Alliance CEO Andy Molnar said via email. “While we are riding a massive swell, the wave hasn’t even begun to crest. The community is expanding and convening this broad coalition of stakeholders is critical to really scale the industry and drive DTx adoption and integration to truly transform healthc…

How medical device companies can benefit from digital therapeutics

Bill Betten

Image courtesy of S3 Connected Health

With so many types of digital health solutions available, device developers could be wondering where the key distinctions lie and which will drive business value for their offerings. Digital Therapeutics (DTx), however, are one subset of digital health products that device developers should keep their eye on. According to the Digital Therapeutics Alliance (DTA), DTx delivers medical interventions using evidence-based, clinically evaluated software to treat a series of conditions. The most notable DTx to date have been software products only, but growing opportunities exist for medical device vendors to create DTx that combine a software element and a device.

These combination DTx offer traditional device-based companies the chance to further their capabilities in digital health and provide a more appealing, competitive product while retaining value a…